Signet Jewelers Facing Activist Pressure For Sale – Could This Be The Turnaround Play of 2025?
In a 13D filing and a pointed letter to the board, Select Equity expressed frustration over Signet’s leadership and stock valuation, citing that shares are trading at less than 6x forward cash earnings.
Stock Market Today: Stock Market Sell-Off Deepens Amid Auto Tariff Concerns
U.S. stocks fell on Wednesday as investors reacted to news that President Trump would announce new tariffs on auto imports.
AvidXchange Holdings: Is This Fintech Player The Next Big Buyout?
AvidXchange Holdings has been in the spotlight following reports that the fintech firm is evaluating a sale after receiving takeover interest.
Altimmune’s Strategic Moves Spark M&A Buzz: Is It The Hottest Player In Obesity & Liver Disease?
Altimmune's recent success on the FDA front escalated when a Betaville "uncooked" alert suggested that the company may be undergoing a strategic review involving at least three large pharma companies.
Americans Lose Confidence in the Economy as Uncertainty and Inflation Weigh on Sentiment
Consumer sentiment took another hit in March as economic uncertainty and rising prices lowered optimism
Stock Market Today: Stocks Waver as Investors Eye Tariff Uncertainty and Economic Data
US stocks traded mixed on Tuesday as investors weighed the latest comments from President Trump on tariffs and looked ahead to key economic reports.
ASBP: Unlocking Multi-Billion Dollar Markets with Enhanced Drug Delivery
Enter Aspire Biopharma, Inc. (NASDAQ: ASBP), a pioneering company enhancing existing drugs with their patent-pending, soluble sublingual technology. By delivering therapeutic levels of medication rapidly and directly into the bloodstream, Aspire is poised to revolutionize how drugs and supplement...